Quince Therapeutics (NASDAQ:QNCX) Upgraded at Citizens Jmp

Citizens Jmp upgraded shares of Quince Therapeutics (NASDAQ:QNCX) from a market perform rating to an outperform rating in a research note issued to investors on Tuesday morning, Marketbeat.com reports. They currently have $77.00 price objective on the stock.

Several other research firms have also commented on QNCX. Craig Hallum upgraded Quince Therapeutics to a “strong-buy” rating in a report on Thursday, August 27th. Weiss Ratings lowered shares of Quince Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 26th. Cantor Fitzgerald restated an “overweight” rating and set a $70.00 price objective on shares of Quince Therapeutics in a research report on Tuesday, August 18th. Lifesci Capital raised shares of Quince Therapeutics to a “strong-buy” rating in a research note on Monday, June 29th. Finally, Citigroup raised shares of Quince Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Quince Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $206.71.

Quince Therapeutics Price Performance

QNCX stock opened at $30.00 on Tuesday. Quince Therapeutics has a 1 year low of $15.10 and a 1 year high of $909.98. The firm has a market capitalization of $30.60 million, a PE ratio of -0.19 and a beta of 1.31. The business has a 50 day simple moving average of $28.41 and a 200-day simple moving average of $23.97.

Quince Therapeutics (NASDAQ:QNCX) last announced its quarterly earnings data on Friday, August 14th. The company reported ($12.31) EPS for the quarter, topping analysts’ consensus estimates of ($28.02) by $15.71.

Hedge Funds Weigh In On Quince Therapeutics

Several large investors have recently modified their holdings of QNCX. BlackRock Inc. purchased a new position in shares of Quince Therapeutics during the 2nd quarter worth $31,000. Intellectus Partners LLC purchased a new position in Quince Therapeutics during the fourth quarter worth about $179,000. Finally, 683 Capital Management LLC purchased a new position in Quince Therapeutics during the fourth quarter worth about $798,000. Institutional investors and hedge funds own 30.75% of the company’s stock.

About Quince Therapeutics

Quince Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for rare diseases. The company’s research centers on its erythrocyte-derived extracellular vesicle (EEV) platform, which uses patients’ red blood cells to encapsulate and deliver therapeutic compounds.

Quince’s lead investigational product is eDSP, formerly known as EryDex, an autologous red-blood-cell-based formulation of dexamethasone sodium phosphate being developed for ataxia-telangiectasia (A-T).